Biomedical subjects

M L Burgos

Publications and source records attributed to M L Burgos.

3 recordsLinked to original sources

PubMed1992

[Program of care of disabled patients at a health center].

OBJECTIVE: To systematise primary attention to the disabled by means of a programme of specific action. To create a Risk Map for the problem of "abandonment of the elderly disabled". DESIGN: Retrospective descriptive study. SITE. El Palo Health Centre (Málaga). First two years of the programme (1989-1991). PATIENTS OR OTHER PARTICIPANTS: Patients with physical and/or mental disability attending to Centre to obtain services. The basic Primary Attention Team. Key informants, the Voluntary Social service. INTERVENTION: Activities: Recruitment strategies: Programme of Planned Home Visits (Subscribers' Register, Individualised Care Plan), Risk Map of Basic Area. RESULTS: 142 patients were included in the first year, and 203 in the second year, carrying out 4.66 and 5.95 programmed visits per patient per year, respectively. The Risk Map defined 28 areas ranked according to risk.

Catchment Area, Health↗

PubMed1991

Dissolution kinetics of bezafibrate in two solid forms for oral administration.

The dissolution kinetics of two solid and oral formulations of bezafibrate have been studied. These preparations are available in the Spanish market. Both of them are tablets, one conventional-release (A) and the other slow-release formulation (C). Dissolution studies have been performed using the system proposed by the USP XXI. The solubility of the drug was determined in each release medium at 37 degrees C. The results indicate that the sink conditions were not satisfied. The evaluation of the dissolution rate-kinetics is performed by three different mathematical approaches. Strong differences in its "in vitro" behaviour were found.

Bezafibrate↗

PubMed1991

In vitro evaluation of the dissolution rate of crystalline suspensions destined to intramuscular administration.

The aqueous suspensions for intramuscular administration belong to the group of the dosage forms, that have a sustained release behaviour. These are based on the low aqueous solubility of the administered molecule whose aqueous suspensions form a depot in the muscular tissue which controls the absorption. The assays performed previously with two molecules of these characteristics have shown the inability of the habitual methods used for evaluating the dissolution rate of a drug, to determine the possible behaviour of these drugs in a definite and concrete formulation. For this reason, we have designed and developed a new method which allows us to support future processes, such as agglomeration and, possibly, cyst forming, that could be developed "in vivo". In this way, a more reliable prediction of the efficiency of inefficiency of this kind of formulation will be possible. Tha validity of our system has been studied with three formulations. Two of them were sustained release cefazolin molecules showing agglomeration problems "in vivo" and the other one a commercial penicillin-G benzathine commercial with a great efficacy demonstrated in habitual clinical practice.

Cefazolin↗